Drugs / CryptiVax-1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07665515 | Jul 2026 → Mar 2029 expected | ovarian serous cystadenocarcinoma | Epitopea Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-24 | Epitopea Ltd | Regulatory Drug Discovery World - Epitopea epitopea.com ↗
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a clinical trial application for a therapy targeting advanced high-grade serous ovarian cancer. |
| 2026-04-23 | Epitopea Ltd | Regulatory Manufacturing Chemist - Epitopea epitopea.com ↗
The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer. |
| 2026-04-23 | Epitopea Ltd | Regulatory European Biotechnology Magazine - Epitopea epitopea.com ↗
Epitopea has received approval from the UK medicines regulator and the Regional Ethics Committee for OVACT, its first-in-human trial of lead candidate CryptiVax-1001 in advanced high-grade serous ovarian cancer. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-24 | Epitopea Ltd | Drug Discovery World - Epitopea epitopea.com ↗ |
| 2026-04-23 | Epitopea Ltd | Manufacturing Chemist - Epitopea epitopea.com ↗ |
| 2026-04-23 | Epitopea Ltd | European Biotechnology Magazine - Epitopea epitopea.com ↗ |
| 2026-04-23 | Epitopea Ltd | Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer - Epitopea epitopea.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CryptiVax-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07665515 ↗ |
| Modality | Messenger RNA (mRNA) | “CryptiVax-1001, a mRNA Lipid Nanoparticle Therapeutic Cancer Vaccine” NCT07665515 ↗ |
| Route | Intramuscular | “i.m injection” NCT07665515 ↗ |